ANVS

Annovis Bio, Inc. (ANVS) | Rumor.io

Annovis Bio

ANVS

Attention (50-day avg)0%

Attention rank (50-day avg)#1,250

Bullish sentiment (50-day avg)63%

Price to earnings ratio-0.99

Market capitalization58.9M

Earnings per share-1.75

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-28.9M

Social

What share of all stock conversation is about ANVS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% 0

Sep 23

Annovis Bio, Inc. (ANVS) announces a strategic partnership with Weave Bio to prepare for the NDA for Buntanetap in Alzheimer's disease, leveraging an AI regulatory platform with FDA-aligned governance.
The company's pivotal AD trial has surpassed enrollment targets, with 862 biomarker-confirmed patients enrolled, exceeding the planned 760 patients.
The AD OLE study for patients completing 18-month FDA AD trial is expected to be a significant catalyst, with biomarker data collected during AD OLE onboarding and patient participation to be closely watched.

Generated by AI

Sentiment

Of the messages about ANVS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	72.73% -4.2	65.54% +3.22	80.9% +9.69
Bearish	—	27.27% +4.2	34.46% -3.22	19.1% -9.69

Bullish· Dec 11

$ANVS has a promising drug candidate that works effectively, and the company is likely to secure funding from investors who believe in its potential.
The stock is experiencing normal market swings, and holding steady or buying the dip could lead to significant gains as the company continues to progress.
With a strong track record of announcements since November 1st, the company's future looks exciting, and patient investors may be rewarded with significant returns in 2026.

Bearish· May 20

The company's management has been accused of prioritizing their own interests over those of shareholders, including issuing unnecessary warrants that dilute shareholder value.
The company is burning through cash at a rate of $6 million per month, and may need to raise an additional $39 million before releasing top-line data from its Phase 3 trial.
The company's failure to secure private funding or a partnership in 2021, when AD stocks were hot, has raised concerns about the effectiveness of its management and the prospects for the company's success.

Generated by AI

Topics

Of the messages about ANVS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	46.34%	46.89%
Analysts	—	0%	0%	16.55%
Technical Analysis	—	0%	51.22%	19.49%
Earnings	—	0%	0%	3.34%
Controversies	—	0%	2.44%	1.33%
Macro	—	0%	0%	12.4%

Announcements· Feb 5

Annovis Bio, Inc. has initiated its Phase 3 clinical trial for early Alzheimer's disease, with the first two patients enrolled.
The trial will evaluate the safety and efficacy of buntanetap, with treatment lasting for 18 months, and aims to enroll over 750 patients across 100 sites in the US.
Annovis has closed a $21 million public offering to advance the development of its Alzheimer's drug, buntanetap, with the funds to be used for clinical development and general corporate purposes.

Technical Analysis· Jul 9

The stock has shown significant strength, with some analysts expecting a drastic pullback, but others believe it will continue to trend up.
The stock has formed a possible cup and handle pattern, with some analysts expecting a retest of the high of day (HOD) or a break above $18.15.
The stock's Relative Strength Index (RSI) has been identified as overbought, with some analysts expecting a correction or a reversal in the stock's trend.

Generated by AI

Community

Of the messages about ANVS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	87.36%	53.62%	69%
Newcomers	0%	12.64%	46.38%	31%

Regulars· Sep 17

The regulars are concerned about the company's ability to raise funds, with one holder stating they will increase their share count only after the next capital raise is finalized.
There is a strong possibility of a reverse split and further dilution, with one participant expecting this to happen after the next capital raise.
The company's CEO, Maria, is under scrutiny for her management of the company, with some participants expressing concerns about her ability to raise funds and questioning the validity of her project.

Newcomers· Nov 26

The stock has shown strong bullish momentum and optimistic market sentiment, with a nearly 20% rise since mid-November, and the short-term trend shows a strong breakout.
Insider buying activity has been observed, with a recent purchase of 34,000 shares worth $159,886, and the upcoming conference may provide additional catalysts for the stock.
The stock has a high price-to-book ratio of 9.71, indicating room for growth in valuation, and an analyst target price of $13.75, making it a key stock to monitor in the long term.

Generated by AI

Annovis Bio (ANVS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

21d agoYahoo Finance

Annovis Bio Targets March 2027 Alzheimer’s Readout, Prepares Rolling NDA

Annovis Bio (NYSE:ANVS) said it expects to report top-line results from the six-month portion of its pivotal Phase III Alzheimer’s disease trial in March 2027, while preparing a rolling new drug application, or NDA, that management said could begin in May if the study meets its efficacy requirements

27d agofinance.yahoo.com

Annovis to Host Corporate Update Webinar on September 2, 2026

MALVERN, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced it will host a corporate update webinar followed by a live Q&A session. The webinar will provide an overview of the Company’s recent progress, ongoing clinical programs, and upc

1mo agoYahoo Finance

Analysts Offer Insights on Healthcare Companies: Annovis Bio (ANVS) and Acurx Pharmaceuticals (ACXP)

Detailed price information for Annovis Bio Inc (ANVS-N) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Biotech Analysis Central Model 10+ Portfolio #15: Annovis Bio; Q1 2027 Buntanetap 6-Month Early AD Results, 18-Month Data Q1 2028, Two Potential NDA Submission Tracks, And Catalysts (NYSE:ANVS)

1mo agoSeeking Alpha

Also Discussed

Investors talking about ANVS also mention

#	Name	Attention
1	Anavex Life Sciences CorpAVXL	0.01%+0
2	Cassava Sciences Inc.SAVA	0%new
3	Avanos Medical Inc.AVNS	0%0
4	BioVie Inc.BIVI	0%0
5	INmune Bio Inc.INMB	0%0
6	AC Immune SAACIU	0%0
7	Biogen IncBIIB	0%-0.01
8	ATHA - Athira Pharma, Inc.	——
9	CYTH - Cyclo Therapeutics, Inc.	——
10	Alector Inc.ALEC	0%new

Annovis Bio, Inc.

Healthcare
Biotechnology

Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. Its current pipeline centers on oral small-molecule candidates designed to address disorders such as Alzheimer’s disease and Parkinson’s disease, with additional programs targeting traumatic brain injury, stroke, Lewy body dementia, and advanced Alzheimer’s disease. The company’s lead candidate, buntanetap, is being studied for chronic neurodegeneration, while ANVS405 and ANVS301 extend its research into acute and later-stage neurological conditions. Annovis Bio’s work is directed at central nervous system disorders where protein misfolding, neuroinflammation, and cognitive decline play key roles. Based in Malvern, Pennsylvania, Annovis Bio operates as a research-driven drug development company within the biotechnology sector.

Website

Location

101 Lindenwood Drive

Malvern, PA, 19355

United States

Social

What share of all stock conversation is about ANVS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% 0

Sep 23

Annovis Bio, Inc. (ANVS) announces a strategic partnership with Weave Bio to prepare for the NDA for Buntanetap in Alzheimer's disease, leveraging an AI regulatory platform with FDA-aligned governance.
The company's pivotal AD trial has surpassed enrollment targets, with 862 biomarker-confirmed patients enrolled, exceeding the planned 760 patients.
The AD OLE study for patients completing 18-month FDA AD trial is expected to be a significant catalyst, with biomarker data collected during AD OLE onboarding and patient participation to be closely watched.

Generated by AI

Sentiment

Of the messages about ANVS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	72.73% -4.2	65.54% +3.22	80.9% +9.69
Bearish	—	27.27% +4.2	34.46% -3.22	19.1% -9.69

Bullish· Dec 11

$ANVS has a promising drug candidate that works effectively, and the company is likely to secure funding from investors who believe in its potential.
The stock is experiencing normal market swings, and holding steady or buying the dip could lead to significant gains as the company continues to progress.
With a strong track record of announcements since November 1st, the company's future looks exciting, and patient investors may be rewarded with significant returns in 2026.

Bearish· May 20

The company's management has been accused of prioritizing their own interests over those of shareholders, including issuing unnecessary warrants that dilute shareholder value.
The company is burning through cash at a rate of $6 million per month, and may need to raise an additional $39 million before releasing top-line data from its Phase 3 trial.
The company's failure to secure private funding or a partnership in 2021, when AD stocks were hot, has raised concerns about the effectiveness of its management and the prospects for the company's success.

Generated by AI

Topics

Of the messages about ANVS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	46.34%	46.89%
Analysts	—	0%	0%	16.55%
Technical Analysis	—	0%	51.22%	19.49%
Earnings	—	0%	0%	3.34%
Controversies	—	0%	2.44%	1.33%
Macro	—	0%	0%	12.4%

Announcements· Feb 5

Annovis Bio, Inc. has initiated its Phase 3 clinical trial for early Alzheimer's disease, with the first two patients enrolled.
The trial will evaluate the safety and efficacy of buntanetap, with treatment lasting for 18 months, and aims to enroll over 750 patients across 100 sites in the US.
Annovis has closed a $21 million public offering to advance the development of its Alzheimer's drug, buntanetap, with the funds to be used for clinical development and general corporate purposes.

Technical Analysis· Jul 9

The stock has shown significant strength, with some analysts expecting a drastic pullback, but others believe it will continue to trend up.
The stock has formed a possible cup and handle pattern, with some analysts expecting a retest of the high of day (HOD) or a break above $18.15.
The stock's Relative Strength Index (RSI) has been identified as overbought, with some analysts expecting a correction or a reversal in the stock's trend.

Generated by AI

Community

Of the messages about ANVS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	87.36%	53.62%	69%
Newcomers	0%	12.64%	46.38%	31%

Regulars· Sep 17

The regulars are concerned about the company's ability to raise funds, with one holder stating they will increase their share count only after the next capital raise is finalized.
There is a strong possibility of a reverse split and further dilution, with one participant expecting this to happen after the next capital raise.
The company's CEO, Maria, is under scrutiny for her management of the company, with some participants expressing concerns about her ability to raise funds and questioning the validity of her project.

Newcomers· Nov 26

The stock has shown strong bullish momentum and optimistic market sentiment, with a nearly 20% rise since mid-November, and the short-term trend shows a strong breakout.
Insider buying activity has been observed, with a recent purchase of 34,000 shares worth $159,886, and the upcoming conference may provide additional catalysts for the stock.
The stock has a high price-to-book ratio of 9.71, indicating room for growth in valuation, and an analyst target price of $13.75, making it a key stock to monitor in the long term.

Generated by AI

Annovis Bio

Social

Sep 23

Bullish· Dec 11

Bearish· May 20

Announcements· Feb 5

Technical Analysis· Jul 9

Regulars· Sep 17

Newcomers· Nov 26

Annovis Bio partners with Weave Bio for NDA preparation

Annovis Bio (ANVS) Loses 26.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Annovis Bio Targets March 2027 Alzheimer’s Readout, Prepares Rolling NDA

Annovis to Host Corporate Update Webinar on September 2, 2026

Analysts Offer Insights on Healthcare Companies: Annovis Bio (ANVS) and Acurx Pharmaceuticals (ACXP)

Biotech Analysis Central Model 10+ Portfolio #15: Annovis Bio; Q1 2027 Buntanetap 6-Month Early AD Results, 18-Month Data Q1 2028, Two Potential NDA Submission Tracks, And Catalysts (NYSE:ANVS)

Also Discussed

Annovis Bio, Inc.

Company Information

Location

Annovis Bio partners with Weave Bio for NDA preparation

Annovis Bio (ANVS) Loses 26.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Annovis Bio Targets March 2027 Alzheimer’s Readout, Prepares Rolling NDA

Annovis to Host Corporate Update Webinar on September 2, 2026

Analysts Offer Insights on Healthcare Companies: Annovis Bio (ANVS) and Acurx Pharmaceuticals (ACXP)

Biotech Analysis Central Model 10+ Portfolio #15: Annovis Bio; Q1 2027 Buntanetap 6-Month Early AD Results, 18-Month Data Q1 2028, Two Potential NDA Submission Tracks, And Catalysts (NYSE:ANVS)

Also Discussed

Social

Sep 23

Bullish· Dec 11

Bearish· May 20

Announcements· Feb 5

Technical Analysis· Jul 9

Regulars· Sep 17

Newcomers· Nov 26